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Abstract
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm characterized by the Philadelphia chromosome and the
related BCR-ABL1 oncoprotein. Acceleration of CML is usually accompanied by basophilia. Several proangiogenic
molecules have been implicated in disease acceleration, including the hepatocyte growth factor (HGF). However, little
is known so far about the cellular distribution and function of HGF in CML. We here report that HGF is expressed
abundantly in purified CML basophils and in the basophil-committed CML line KU812, whereas all other cell types
examined expressed only trace amounts of HGF or no HGF. Interleukin 3, a major regulator of human basophils,
was found to promote HGF expression in CML basophils. By contrast, BCR-ABL1 failed to induce HGF synthesis in
CML cells, and imatinib failed to inhibit expression of HGF in these cells. Recombinant HGF aswell as basophil-derived
HGF induced endothelial cell migration in a scratch wound assay, and these effects of HGF were reverted by an anti-
HGF antibody as well as by pharmacologic c-Met inhibitors. In addition, anti-HGF and c-Met inhibitors were found
to suppress the spontaneous growth of KU812 cells, suggesting autocrine growth regulation. Together, HGF is a
BCR-ABL1–independent angiogenic and autocrine growth regulator in CML. Basophils are a unique source of HGF
in these patients and may play a more active role in disease-associated angiogenesis and disease progression than
has so far been assumed. Our data also suggest that HGF and c-Met are potential therapeutic targets in CML.
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Introduction
Chronic myeloid leukemia (CML) is a hematopoietic neoplasm char-
acterized by the reciprocal chromosome translocation t(9;22) [1]. This
cytogenetic defect creates the BCR-ABL1 fusion gene [2,3]. The asso-
ciated oncoprotein, BCR-ABL1, is a cytoplasmic molecule that exhib-
its constitutive tyrosine kinase activity and triggers key downstream
signaling molecules, including RAS, the phosphoinositide 3-kinase,
and STAT5 [4–6]. BCR-ABL1 and various BCR-ABL1 downstream
signaling molecules have been implicated as major triggering factors in
the pathogenesis of CML. In line with this assumption, BCR-ABL1–
targeting drugs such as imatinib, are successfully used to suppress the
growth of neoplastic cells in patients with CML [7,8].
The clinical course in CML can be divided into a chronic phase
(CP), an accelerated phase (AP), and a blast phase (BP), which is the
terminal phase and resembles an acute leukemia [8–10]. Whereas in
CP, BCR-ABL1 is a major driving force of cell survival and prolifera-
tion, additional factors and pro-oncogenic molecules, apart from BCR-
ABL1, may play a more important or even decisive pathogenetic role in
AP and BP [6–10]. A key feature in AP of CML is basophilia [11,12].
Moreover, basophilia is one of the most significant prognostic factors
in CML at diagnosis [12,13].
Although little is known about disease initiation and evolution in
CML, several mechanisms and molecules have been implicated as
potential mediators of acceleration and drug resistance, including
survival-related molecules, cytokine receptors, and various signal
transduction pathways [4–10,14,15]. In addition, increased angio-
genesis in the bone marrow (BM) and other hematopoietic tissues
may contribute to disease progression in CML [16–18].
A number of angiogenic cytokines have been identified in CML
cells, including vascular endothelial growth factor (VEGF), basic fibro-
blast growth factor, angiopoietin 1, and matrix metalloproteinases
[17–22]. In addition, hepatocyte growth factor (HGF) has been de-
scribed to be expressed in CML cells [23,24]. In particular, it has been
described that patients with CML exhibit elevated HGF levels in their
BM and blood and that HGF expression in the BM correlates with
microvessel density [23,24]. Moreover, recent data suggest that in-
creased blood levels of HGF correlate with the prognosis in these
patients [25]. However, so far, little is known about the cellular source
and function of HGF in CML cells and the exact role this cytokine
plays in the pathogenesis of CML.
In the current study, we show that HGF is preferentially produced
in CML basophils, and that basophil-derived HGF triggers endothelial
cell migration and growth through a specific receptor. These obser-
vations point to a novel hitherto unrecognized and more active role
of basophils and their products in disease acceleration in CML. In




The basophil-specific PE-labeled monoclonal antibody (mAb)
97A6 (CD203c) [26] was purchased from Immunotech (Marseille,
France), a polyclonal rabbit anti-HGF antibody (H-145) from Santa
Cruz Biotechnology (Santa Cruz, CA), rabbit anti–phospho-c-Met
mAb D26 (Tyr1234/1235) from Cell Signaling (Danvers, MA),
biotinylated anti-rabbit IgG and Vectastain Universal ABC-AP Kit
from Vector Laboratories (Burlingame, CA), and biotinylated goat
anti-rabbit IgG from Biocare Medical (San Diego, CA). The basophil-
specific mAb BB1 [27] was produced at the University of Southampton,
United Kingdom. A specification of antibodies is shown in Table W1.
The c-Met inhibitors PF-2341066 and SU11274 were purchased from
Selleck Chemicals (Houston, TX). The protoscript first-strand com-
plementary DNA (cDNA) synthesis kit was from New England Biolabs
(Beverly, MA), RPMI-1640 medium, Iscove modified Dulbecco me-
dium (IMDM) and fetal calf serum (FCS) from PAA Laboratories
(Pasching, Austria), recombinant human (rh) VEGF, and medium
199 from Invitrogen (Camarillo, CA), rhHGF from Sigma-Aldrich
(St Louis, MO), endothelial cell growth supplement from Technoclone
(Vienna, Austria), and rh granulocyte-macrophage colony stimulating
factor (GM-CSF), and murine interleukin 3 (IL-3) from PeproTech
(Rocky Hill, NJ). Imatinib was kindly provided by Drs E. Buchdunger
and P.W. Manley (Novartis Pharma AG, Basel, Switzerland).
Isolation and Culture of Primary CML Cells
Primary leukemic cells were obtained from 25 patients with un-
treated CP CML and 7 with AP CML. BM aspirate samples (iliac crest)
and peripheral blood (PB) cells were collected in heparinized tubes.
Normal BM cells were obtained from three patients with lymphoma
(routine staging) without BM involvement. Informed consent was
obtained from each patient before blood donation or BM puncture.
BM mononuclear cells (MNCs) and PB MNC were isolated using
Ficoll. The study was approved by the institutional review board of
the Medical University of Vienna. Isolated MNCs were cultured in
RPMI-1640 medium containing 10% FCS with or without cyto-
kines. In four patients with CML with marked basophilia, PB MNCs
were separated into two fractions by cell sorting: a CD203c+ fraction
(>98% basophils) and a CD203c− fraction (<1% basophils) using the
CD203c mAb 97A6 as described [26]. In three patients with CML,
CD34+/CD38− stem cells and CD34+/CD38+ progenitor cells were
enriched to greater than 98% purity by cell sorting using a PE-labeled
CD34 mAb (clone 581) and an APC-conjugated mAb against CD38
(HIT2) (Table W1). Cell sorting was performed on a FACS-Aria (BD
Biosciences, San Jose, CA). After sorting, cell viability was more than
95% in all experiments.
Cell Lines and Culture Conditions
Ton.B210-X is an IL-3–dependent Ba/F3–derived cell line, in which
BCR-ABL1 can be induced conditionally through addition of doxy-
cycline (1 μg/ml) [21]. Ton.B210-X cells were grown in RPMI-1640
medium with 10% FCS and IL-3 (1 ng/ml) at 37°C. For starvation,
cells were cultured in the absence of IL-3 for up to 24 hours [21]. The
BCR-ABL1+ cell lines K562 (multilineage) and KU812 (basophil-
committed), the BCR-ABL1− cell lines HL60, KG1, U937, and MO7e,
as well as lung fibroblasts (LUFs), were maintained in RPMI-1640
medium and 10% FCS. MO7e cells were transfected with BCR-
ABL1 by lentiviral-mediated gene transfer as described [28]. Whereas
control MO7e cells (nontransfected and empty vector transfected) were
cultured in GM-CSF (100 ng/ml), BCR-ABL1–transfected MO7e
cells (MO7e-p210) were maintained without GM-CSF. HMC-1.1
and HMC-1.2 cells were maintained in Iscove modified Dulbecco
medium plus 10% FCS. To inhibit BCR-ABL1 activity, KU812 cells
were cultured in imatinib (1 μM) for up to 8 hours. After exposure
to imatinib, cells were subjected to quantitative polymerase chain re-
action (qPCR) and ELISA measurements. Human umbilical vein–
derived endothelial cells (HUVECs) were purchased from Technoclone
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and cultured at 37°C and 5% CO2 in gelatin-coated plastic flasks in
Medium 199 supplemented with endothelial cell growth supplement
(20 μg/ml).
Northern Blot Analysis and qPCR
Northern blot analysis was performed as described previously
[21]. Total RNA was extracted from leukemic cell lines using TRIzol
(Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions.
Twenty micrograms of RNA was size fractionated on 1.0% formal-
dehyde agarose gels and transferred to nylon membranes (Hybond N;
Amersham, Aylesbury, United Kingdom) [21]. Hybridization was per-
formed with 32P-labeled cDNA probes (Table W2), and labeling was
conducted using MegaPrime kit (Amersham). Blots were washed in
0.2 × SSC (1 × SSC = 150 mM NaCl and 15 mM sodium citrate,
pH 7.0) with 0.1% sodium dodecyl sulfate [21]. Bound radioactivity
was visualized by exposure to Biomax MS films (Kodak, Rochester,
NY) at −80°C using intensifying screens. For PCR analysis, total RNA
was isolated from cell lines and primary leukemic cells (patients with
CML CP: BM, n = 14 and PB, n = 20; AP: BM, n = 8; and PB,
n = 12) using the RNeasy MinElute Cleanup Kit (Qiagen, Hilden,
Germany). Complementary DNA was synthesized using Moloney
murine leukemia virus reverse transcriptase (Invitrogen), random prim-
ers, first-strand buffer, dNTPs (100 mM), and RNasin according to
the manufacturer’s instructions (Invitrogen). Quantitative PCR was
performed as described [28] using iTaq SYBR Green SuperMix with
ROX (Bio-Rad, Hercules, CA) and primers specific for HGF, c-Met,
histidine decarboxylase (HDC), VEGF, and ABL (Table W3).
Immunohistochemistry and Immunocytochemistry
In 16 patients with CP CML, 14 with AP, 6 with BP, and 5 with
normal BM, expression of HGF was analyzed by IHC on serial sec-
tions (2 μm) prepared from formalin-fixed, paraffin-embedded, BM
specimens. IHC was performed by the indirect immunoperoxidase
staining technique as described [29] using a polyclonal anti-HGF anti-
body (work dilution, 1:50) and the anti-basophil mAb BB1 (1:300).
After incubation (overnight) slides were washed, incubated with bio-
tinylated second step goat anti-rabbit or horse anti-mouse antibodies
(30 minutes), washed, and stained using 3-amino-9-ethyl-carbazole
(Sigma-Aldrich). Slides were counterstained in Meyer hematoxylin.
For ICC, primary CML cells (CML CP: BM, n = 17, and PB, n =
17; AP: BM, n = 8, and PB, n = 10) and cell lines were spun on
cytospin slides and incubated with the anti-HGF antibody (1:50) or
with mAb BB1 (1:300) overnight. Then, slides were washed and
incubated with a biotinylated goat anti-rabbit antibody for 30 minutes.
Slides were again washed and incubated with streptavidin alkaline phos-
phatase complex (30 minutes), washed, and stained with New Fuchsin
(Nichirei Corporation, Tokyo, Japan).
Flow Cytometry
To investigate expression of c-Met on cell lines, and HUVEC,
flow cytometry was performed using fluorochrome-conjugated
mAb (Table W1). Multicolor flow cytometry was performed on a
FACSCalibur (BD Biosciences) using FlowJo software (TreeStar,
Ashland, OR). Antibody reactivity was controlled by isotype-matched
antibodies. In a separate set of experiments, CML cells were incubated
(37°C, 5% CO2) with the c-Met inhibitor PF-2341066 (1 μM, 24 or
48 hours) and were then examined for signs of apoptosis by combined
staining for surface antigens and Annexin V–fluoresceine isothiocyanate
and caspase 3, following the instructions of the manufacturer (Bender
MedSystems, Vienna, Austria).
Evaluation of Proliferation of CML Cells and
Endothelial Cells
CML cells (primary CMLMNC and cell lines: K562, KU812) were
incubated in control medium, HGF (100 ng/ml), VEGF (100 ng/ml),
or KU812 supernatants in the absence or presence of the c-Met in-
hibitors PF-2341066 or SU11274 (each 0.01-10 μM) for 48 hours
(37°C, 5% CO2). After incubation, proliferation was determined by
measuring 3H-thymidine incorporation in 96-well microtiter plates
(CML cells: 5 × 104 cells per well). After incubation, 3H-thymidine
(0.5 μCi) was added to each well. Sixteen hours later, cells were har-
vested on filter membranes (Packard Bioscience, Meriden, CT) in a
Filtermate 196 harvester (Packard Bioscience). Filters were then air-
dried, and the bound radioactivity was measured in a β-counter (Top-
Count NXT; Packard Bioscience). All experiments were performed
in triplicates.
Measurement of HGF and VEGF by ELISA
HGF and VEGF were measured in lysates and supernatants of
cultured primary CML cells and KU812 cells (1 × 107 cells per well)
after incubation in control medium in the presence or absence of cyto-
kines (IL-3; 100 ng/ml). In a separate set of experiments, KU812 cells
were incubated in control medium or in medium containing various
concentrations of imatinib (0.1-1 μM) for 24 or 48 hours. HGF and
VEGF concentrations were determined by ELISA (R&D Systems,
Minneapolis, MN).
Endothelial Cell Migration (Scratch Wound) Assay
To demonstrate functional activity of basophil-derived HGF, we
applied basophil supernatants and KU812 supernatants as well as
K562 supernatants (control) in a scratch assay. In this assay, HUVEC
were seeded in six-well plates and cultured at 37°C in 5% CO2 until
confluence was reached. A linear scratch wound (100 μm diameter)
was produced by a pipette tip. Endothelial migration was induced by
adding rhVEGF (100 ng/ml) and/or rhHGF (100 ng/ml). In addition,
cell supernatants were applied at various dilutions (1:1, 1:4, 1:8, 1:16,
and 1:32) with or without rhVEGF (100 ng/ml), a polyclonal block-
ing anti-HGF antibody (60 ng/ml), anti-VEGF antibody (100 ng/ml),
or the c-Met inhibitor PF-2341066 (1 μM). After 24 and 48 hours,
endothelial cell migration was examined in an inverted microscope
(Olympus, Hamburg, Germany), photographed (Eclipse TE 300;
Nikon, Tokyo, Japan) and graded using the following scores: 0 =
scratched areas empty, 1 = few single endothelial cells in scratch
wound, 2 = multiple isolated endothelial cells in the scratch lesion,
3 = endothelial cells form aggregates and bridges in scratch wound,
and 4 = scratch wound completely “healed” with confluent endothelial
layer (Figure W1).
Statistical Analysis
Data were analyzed by Student’s t test, Mann-Whitney U test, one-
way analysis of variance, and Kruskal-Wallis test using GraphPad Prism
5.0 (GraphPad Software, La Jolla, CA). The Student’s t test was used
to compare differences between two experimental groups, whereas
one-way analysis of variance (followed by Bonferroni adjustment)
was applied to analyze differences between three or more groups.
Results were considered to be significantly different when P < .05.
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Results
Expression of HGF in Primary CML Cells
As assessed by immunocytochemistry (ICC) and immunohisto-
chemistry (IHC), primary CML cells were found to express the
HGF protein (Figure 1, A-D). In both staining protocols (ICC
and IHC), only a subset of leukemic cells were found to react with
the anti-HGF antibody (Figure 1, A-D). The percentage of HGF-
positive cells varied from patient to patient and was higher in patients
with AP compared to patients with CP or BP (Figure 1, A-D; P <
.05). The difference in HGF expression in BM cells in the various
phases of CML was clearly demonstrable in our ICC staining experi-
ments as well as in the IHC protocol. Preincubation of the anti-HGF
antibody with a HGF-specific blocking peptide resulted in a negative
stain (Figure W2). We were also able to demonstrate expression of
HGF mRNA in primary CML cells by qPCR. As expected, HGF
transcript levels were found to be higher in CML cells in AP com-
pared to patients with CP (Figure 1E ; P < .05).
Identification of Basophils as a Major Source of HGF in CML
On the basis of the observation that HGF is expressed at high
levels in leukemic cells in AP, we examined the expression of HGF
in basophils, known to increase substantially in AP [11,12]. As shown
in Figure 2A, sorted CD203c+ CML basophils were found to express
substantial amounts of HGF mRNA, whereas basophil-depleted cell
fractions contained only low amounts of HGF mRNA. Moreover,
we were able to show that supernatants of basophil-rich cell fractions
contain substantial amounts of the HGF protein, whereas supernatants
of CML samples with low numbers of basophils, exhibited no de-
tectable HGF (Figure 2B). In a next step, we established correlations
between HGF+ cells and basophil numbers in our immunostaining
experiments. On cytospin slides, basophils were identified and counted
after Wright-Giemsa staining, and the numbers of HGF+ cells were
determined by ICC. In BM biopsy sections, basophils were quantified
by BB1 staining, and the numbers of HGF+ cells were determined
on adjacent BM sections by IHC. In both analyses, we found a good
correlation between the numbers (percentage) of basophils and the
numbers (percentage) of HGF+ cells (Figure 2, C and D), confirming
that basophils are a primary source of HGF in the BM and PB in CML.
The Basophil-Committed CML Cell Line KU812
Produces HGF
In a next step, we examined HGF expression in various leukemic
cell lines including the basophil-committed CML line KU812, the
immature (uncommitted) CML line K562, HUVECs, and LUFs. As
shown in Figure 3A, KU812 cells were found to express substantial
amounts of HGF mRNA, whereas K562 cells and the other leukemic
cell lines tested did not express substantial amounts of HGF mRNA.
Correspondingly, KU812 cells, but neither K562 cells nor the other
leukemic cell lines tested, were found to express and release the HGF
protein (Figure 3B). Moreover, KU812 cells, but not the other leukemic
cell lines tested, were found to stain positive for HGF by ICC (Fig-
ure 3C). HUVEC and LUF, known to express HGF, served as a positive
control. Preincubation of the anti-HGF antibody with a HGF-specific
blocking peptide resulted in a negative stain (Figure W2). We also ex-
amined expression of c-Met in various cell lines. As assessed by Northern
blot analysis and qPCR, KU812 cells and LUFs were found to express
c-Met mRNA, whereas the other cell lines tested expressed only low
or undetectable amounts of c-Met mRNA (Figure 3D). Similar results
were obtained by flow cytometry. Again, KU812 cells were found to
display substantial amounts of c-Met (Figure 3E). Unexpectedly, K562
cells were also found to express c-Met on their surface, although ex-
pression levels were lower compared with KU812 cells. As expected,
HUVEC expressed c-Met on their surface (positive control; Figure 3E).
Expression of HGF in CML Cells Is Independent
of BCR-ABL1
The CML-specific oncoprotein BCR-ABL1 supposedly contributes
to the expression of various angiogenic growth factors in leukemic cells
[18,19,21]. In the present study, we asked whether BCR-ABL1 is in-
volved in the regulation of expression of HGF. In a first step, we ex-
amined the expression of Hgf mRNA in Ton.B210-X cells in which
BCR-ABL1 can conditionally be induced by adding doxycycline.
However, as shown in Figure 4A, BCR-ABL1 did not induce the
expression of Hgf in Ton.B210-X cells, whereas BCR-ABL1 induced
the expression of Hdc mRNA in the same experiment. In line with
this observation, we were not able to detect any differences in expres-
sion of HGF mRNA levels or HGF protein levels when comparing
untransfected (or control vector transfected) MO7e cells with MO7e
cells stably transfected with BCR-ABL1 (Figure 4B). We also asked
whether the BCR-ABL1 inhibitor imatinib would modulate the ex-
pression of HGF mRNA (or the HGF protein) in KU812 cells. How-
ever, no effect of imatinib on expression of HGF mRNA was found,
whereas imatinib caused down-regulation of expression of VEGF
mRNA and HDC mRNA in these experiments (Figure 4C ). More-
over, although inducing rapid apoptosis in KU812 cells, imatinib did
not substantially suppress HGF expression or HGF release in KU812
cells (Figure 4D). All in all, these data suggest that HGF production in
CML cells is regulated independent of BCR-ABL1.
IL-3 Regulates the Expression and Release of HGF in
CML Cells
We next asked whether IL-3, a major regulator of basophil differ-
entiation and function [30,31], would promote the production and
expression of HGF in CML cells. Indeed, IL-3 was found to upregulate
the expression of HGF mRNA in purified CML basophils (Fig-
ure W3). Moreover, IL-3 was found to promote the expression and
release of the HGF protein in unfractionated primary CML MNC
(Figure W3). By contrast, IL-3 failed to upregulate the expression or
release of VEGF in CML cells (not shown).
Basophil-Derived HGF Promotes Endothelial Cell
Migration In Vitro
To define a functional role for basophil-derived HGF, we measured
the effects of supernatants derived from KU812 cells or primary CML
cells on endothelial cell growth and migration using HUVEC and
a wound healing (scratch) assay. In these experiments, recombinant
HGF as well as supernatants from KU812 cells, induced endothelial
growth and migration, whereas supernatants of K562 cells showed
no effects (Figure 5A). In addition, we found that supernatants of
basophil-rich primary CML samples induced endothelial cell migra-
tion, whereas supernatants of primary samples containing low numbers
of (or no) basophils did not induce wound healing (Figure 5A). CML
supernatant-induced migration of HUVEC was completely blocked
by a neutralizing anti-HGF antibody and partly by the addition of
an anti-VEGF antibody (Figure 5B). In addition, we were able to show
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Figure 1. Detection of HGF in primary CML cells. (A) Ficoll-isolated PB cells obtained from patients with CML in CP or AP were spun on
cytospin slides and stained by Wright-Giemsa (upper panels) or with an antibody against HGF (lower panels) by indirect ICC (magnification,
100×/1.35). (B) Percentage of basophils (left panel) and HGF-positive cells (right panel) counted in PB and BM samples obtained from pa-
tients with CML CP (n = 17) and CML AP (n = 10) by ICC. Results represent the mean ± SD from all patients. *P < .05. (C) Immuno-
histochemical (IHC) detection of BB1 and HGF in BM cells. Serial sections were prepared from paraffin-embedded BM (iliac crest) in a
patient in CML CP (left panels), one with CML AP (middle panels), and one in BP (right panels). Sections were stainedwith antibodies against
BB1 (upper panels) or HGF (lower panels). Magnification, 40×/0.85. (D) Percentage of BB1-positive basophils (left panel) and HGF-positive
cells (right panel) in BM sections obtained from patients with CML CP (n = 16), CML AP (n = 14), CML BP (n = 6), or control marrow
(n= 5). Expression of BB1 and HGF was examined by IHC. Results represent the mean ± SD from all donors in each group. *P< .05 com-
pared with control (normal BM). (E) Expression of HGFmRNA in primary CML cells. Ficoll-isolated cells (PB: CP, n=20; AP, n=12; BM: CP,
n= 14; AP, n= 8) were subjected to RNA isolation and qPCR using primers specific forHGF and ABL. Results showHGFmRNA expression
levels as percent of ABL mRNA levels. Results represent the mean ± SD from all donors in each group. *P < .05.
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that the CML supernatant-induced endothelial cell migration was
blocked by the c-Met inhibitor PF-2341066 (Figure 5C). As expected,
migration of HUVEC induced by recombinant HGF was also blocked
by the c-Met inhibitor PF-2341066 and by an anti-HGF antibody
but not by an anti-VEGF antibody (Figure W4). Together, these data
show that basophil-derived HGF and VEGF are functionally active
proangiogenic molecules.
Expression of c-Met mRNA in CML Basophils and CML
Progenitor Cells
We next examined whether the HGF receptor c-Met is expressed
in primary CML cells. In a first step, we examined highly enriched
sorted CD34+/CD38− stem cells and CD34+/CD38+ progenitor cells
in patients with CML AP. As assessed by qPCR, CML stem cells and
CML progenitor cells were found to express low but detectable levels
of c-Met mRNA (Figure 6A). In addition, we found that highly en-
riched CML basophils (CP CML) express low levels of c-Met mRNA
(Figure 6B). IL-3 was found to promote c-Met mRNA expression in
unfractionated CML MNC as well as in highly enriched CML baso-
phils (Figure 6B). We were also able to show that KU812 cells express
c-Met mRNA (Figure 3D). As assessed by flow cytometry, c-Met
was found to be expressed on KU812 cells and K562 cells as well as
on HUVEC (positive control; Figure 3E ). However, unexpectedly,
we were unable to detect substantial amounts of c-Met on the surface
of unstimulated or IL-3–exposed (CD34+/CD38−) CML stem cells or
CML basophils (Figure W5).
Effects of HGF on Growth of CML Cells
A number of recent data suggest that angiogenic growth factors,
apart from their angiogenic activity, may also act as autocrine growth
regulators in leukemic cells. To ask whether HGF can act as a growth
regulator in CML cells, we applied HGF and a blocking anti-HGF
Figure 2. Identification of basophils as a source of HGF in CML. (A) Expression of HGF mRNA in unfractionated PB MNCs, highly purified
sorted CD203c+ basophils (BA+), and basophil-depleted (BA−) cells. MNC were prepared from PB of three CML donors. mRNA levels were
quantified by qPCR using primers specific for HGF and ABL. Results show HGF mRNA levels as percent of ABL mRNA levels and repre-
sent the mean ± SD from three donors. *P < .05 compared with MNC. (B) Measurement of HGF protein levels in supernatants of cultured
PB cells (5-day culture) obtained from three patients with CML with marked basophilia (>10%) and three patients with CML with low baso-
phil counts (≤2%). HGF levels were determined by ELISA. Results represent the mean ± SD of three donors. (C) Correlations between
HGF+ cells and basophils (Wright-Giemsa stain) in BM MNC samples (n = 20, left panel) and PB MNC (n = 17, right panel) of patients
with CML. The numbers (percentage) of HGF+ cells were determined by IHC. R indicates the correlation coefficient. (D) Correlation be-
tween HGF+ cells and BB1+ cells (percentage of nucleated cells) in BM sections in patients with CML (n= 29). Adjacent BM sections were
stained with antibodies against HGF and BB1 by IHC. R indicates the correlation coefficient.
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Figure 3. Expression of HGF and c-Met in various leukemic cell lines. (A) Evaluation of expression of HGF mRNA in various leukemic cell
lines, and LUFs by Northern blot analysis (NB left side) and qPCR (right side). β-Actin (NB) and ABL (qPCR) served as control. (B) Measure-
ment of HGF in supernatants of leukemic cell lines, HUVECs, and LUF. Supernatants were obtained after culturing cells in medium with
10% FCS for 5 days. HGF concentrations were determined by ELISA. Results represent the mean ± SD of three independent experiments.
(C) ICC evaluation of HGF expression in leukemic cell lines, LUFs and HUVECs. Cells were spun on cytospin slides and stained with
an antibody against HGF. Magnification, 100×/1.35. (D) Evaluation of expression of c-Met mRNA in various leukemic cell lines and LUFs
by Northern blot analysis (NB; left panel) and qPCR (right panel). β-Actin (NB) and ABL (qPCR) served as control. (E) Surface expression
of c-Met on KU812, K562, HMC-1.1, HMC-1.2, HL60, KG-1, U937, LUF, and HUVEC. Cells were analyzed for expression of c-Met by flow
cytometry. Expression of c-Met (red histograms) was controlled by an isotype-matched antibody (black open histograms).
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Figure 4. Expression of HGF in CML cells is independent of BCR-ABL1. (A) Expression of Hdc mRNA and Hgf mRNA in Ton.B210-X cells
determined by qPCR. Cells were cultured in the presence (DOXY) or absence (CO) of doxycycline (1 μg/ml) for 24 hours to induce BCR-
ABL1 and were then subjected to RNA isolation, cDNA synthesis, and qPCR using primers specific for Hdc, Hgf, and Actin. Results show
Hdc mRNA expression levels and Hgf mRNA expression levels as copies/105 copies of Actin. Results represent the mean ± SD of three
independent experiments. *P< .05. (B) Expression of HGF, HDC and VEGFmRNA inMO7e cells stably transfectedwith BCR-ABL1 (p210) or
with a control vector (CO) determined by qPCR. Cells were cultured in the absence (−GM-CSF) or presence (+GM-CSF) of GM-CSF (100 ng/
ml) for 24 hours and were then subjected to RNA isolation, cDNA synthesis, and qPCR using primers specific forHGF,HDC, VEGF, and ABL.
Results showHDC and VEGFmRNA levels as percent of ABLmRNA levels and represent themean± SD of three independent experiments.
*P < .05. (C) Effects of imatinib on expression of HGF, HDC, and VEGF mRNA in KU812 cells. Cells were cultured in the absence (CO)
or presence of imatinib (1 μM) for 8 hours and were then subjected to qPCR analysis using primers specific for HGF, HDC, VEGF, and
ABL. Results show HGF, HDC, and VEGF mRNA levels as percent of ABL mRNA, and represent the mean ± SD of three independent
experiments. (D) Measurement of HGF in supernatants of KU812 cell. Supernatants were obtained after culturing cells in medium with
10% FCS in the absence (CO) or presence of imatinib at 0.1 and 0.5 μM for 24 hours. HGF concentrations were determined by ELISA.
Results represent the mean ± SD of three independent experiments.
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Figure 5. Effects of basophil-derived HGF on endothelial cell migration. (A) Effects of rhHGF and CML-derived HGF onmigration of HUVECs
in a scratch wound assay. Confluent HUVEC layers were prepared in six-well plates. A linear scratch wound (≈100 μm diameter) was pro-
duced by a pipette tip. Then, HUVECswere cultured in control medium (CO), rhHGF (100 ng/ml), or 5-day supernatants (Sup.) of KU812 cells,
K562 cells (HGF-negative), and primary CMLcells (CML-enriched fractions,>10%basophils; andCML fractions containing<2%basophils=
negative control). After 24 hours, migration of HUVEC was examined under an inverted microscope magnification: 4×/0.13. The scratch
wound is marked by white bars. (B) Effects of a neutralizing anti-HGF antibody (αHGF) and a neutralizing anti-VEGF antibody (αVEGF)
on migration of HUVECs determined by scratch wound migration assay. After introducing a scratch wound, HUVECs were incubated
with supernatants (Sup.) of primary basophil-rich CML cells (>10% basophils) or KU812 cells in the absence (−) or presence (+) of αHGF
(60 ng/ml) or/and αVEGF (100 ng/ml) as indicated. After 24 hours (37°C), migration of HUVECs was examined under an inverted microscope
and photographed. Cell density in the scratch was scored from 0 to 4 as shown in Figure W1. Results represent the mean ± SD of three
independent experiments. (C) Effects of the c-Met inhibitor PF-2341066 on migration of HUVECs induced by KU812 cell supernatant (left
panel) or supernatant of primary basophil-rich cells (right panel). After a linear scratch was produced, HUVEC monolayers were incubated
with supernatants of CML cells in the absence (CO) or presence of various concentrations of PF-2341066 as indicated. After 24 hours,
migration of HUVECs was examined under an inverted microscope and photographed. Cell density in the scratch was scored from 0 to
4 as shown in Figure W1. Results represent the mean ± SD of three independent experiments.
580 Basophils as a Source of HGF in CML Cerny-Reiterer et al. Neoplasia Vol. 14, No. 7, 2012
antibody on CML cells. We found that HGF slightly promotes the
proliferation of primary CML cells (Figure W6) and KU812 cells
(Figure 6C). In addition, we found that a blocking anti-HGF antibody
counteracts spontaneous proliferation of KU812 cells (Figure 6D).
These data suggest that HGF is a regulator of autocrine growth of
(basophil-committed) CML cells.
Effects of c-Met Inhibitors on Growth of CML Cells
A number of different pharmacologic c-Met inhibitors have been
developed during the past few years. In this study, we examined the
effects of the c-Met inhibitors PF-2341066 and SU11274 on growth
of CML cells. Both inhibitors were found to suppress spontaneous
proliferation of KU812 cells and K562 cells in a dose-dependent
manner (IC50 = 1-5 μM; Figure 7A). In addition, PF-2341066 and
SU11274 were found to inhibit 3H-thymidine uptake in primary
CML cells (BM or PB MNC) in all patients tested, with an IC50 of
about 1 μM (Figure 7B). The growth-inhibitory effects of the c-Met
inhibitor PF-2341066 (in KU812 cells) was found to be accompanied
by signs of apoptosis (Figure 7C , D). SU11274 also induced apoptosis
in CML cells. However, SU11274-exposed cells also showed signs
of necrosis after 24 hours, so that the exact numbers (percentage) of
apoptotic cells could not be determined. To confirm drug effects on
c-Met kinase activity, ICC was performed using an antibody specific for
phospho-c-Met. In these experiments, both PF-2341066 and SU11274
were found to inhibit expression of p-c-Met in KU812 cells (Figure 7E).
Discussion
HGF is an established mediator of angiogenesis and is considered
to play an important role in the pathogenesis of various myeloid
neoplasms [16–22]. In CML, increased levels of HGF have been de-
scribed as a prognostic variable that correlates with survival [23–25].
It has also been described that HGF levels correlate with BM angio-
genesis. However, so far, little is known about the regulation of HGF
expression and the cellular source of HGF in CML. We here describe
that basophils are a major source of HGF in CML and that basophil-
derived HGF promotes endothelial cell migration in vitro. In addition,
our data show that basophil-derived HGF acts on endothelial cells
through a specific receptor, c-Met, and that the effects of HGF can
be blocked by anti-HGF antibodies as well as by c-Met inhibitors.
Together, these data suggest that basophils may play a more active
role in disease acceleration in CML than has so far been assumed.
Figure 6. Expression of c-Met on CML progenitor cells and CML basophils. (A) Expression of c-Met mRNA in highly enriched (sorted)
CD34+/CD38− stem cells and CD34+/CD38+ progenitor cells obtained from patients with CML in AP as determined by qPCR. Cells were
subjected to RNA isolation, cDNA synthesis, and qPCR using primers specific for c-Met and ABL. Results show c-Met mRNA levels as
percent of ABL mRNA levels and represent the mean ± SD of three independent experiments (three patients). (B) Expression of c-Met
mRNA in PB MNCs and highly purified CD203c+ basophils (BA+) from three patients with CML. MNCs and basophils were incubated in
the absence (CO) or presence of IL-3 (100 ng/ml) for 30minutes and were then subjected to RNA isolation, cDNA synthesis, and qPCR using
primers specific for c-Met andABL. Results showHGFmRNA expression levels as percent of ABLmRNA levels and represent themean±SD
of three independent experiments (three donors). *P < .05. (C) KU812 cells were incubated in control medium (CO) or in medium contain-
ing various concentrations of rhHGF at 37°C for 48 hours. Then, uptake of 3H-thymidine was measured. Results are expressed as percent of
control and represent the mean ± SD of three independent experiments. *P < .05. (D) KU812 cells were incubated in control medium (CO)
or in medium containing an anti-HGF antibody (αHGF; 1 μg/ml) or a control antibody (CO IgG; 1 μg/ml) at 37°C for 48 hours. Then, uptake
of 3H-thymidine was measured. Results are expressed as percent of CO and represent the mean ± SD of three independent experiments.
*P < .05.
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In addition, our data suggest that basophil-derived HGF as well as
c-Met may serve as novel potential targets in CML.
Recent data suggest that HGF expression correlates with the phase
of disease and the prognosis in CML [23–25]. In the current study,
we were able to confirm these data. In particular, we were able to show
that HGF mRNA levels are higher in leukemic cells in patients with
AP compared to those in patients with CP. Because progression of
CML is usually accompanied by an increase in basophils [11–13],
we asked whether basophils are a particular source of HGF in CML.
Although these cells are well known to produce an array of vascular
and angiogenic mediators [32–34], they have not been analyzed for
expression of angiogenic growth factors in CML so far. In the present
study, we were able to show that basophils are a unique source of HGF
in CML. In particular, primary isolated CML basophils were found
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to express substantial amounts of HGF mRNA as well as the HGF
protein, whereas basophil-depleted cell fractions contained only low
amounts of HGF. Moreover, we found that the basophil-committed
CML cell line KU812 expresses substantial amounts of HGF mRNA
and the HGF protein, whereas other leukemic cell lines tested, includ-
ing the immature uncommitted CML cell line K562, expressed only
low amounts or no detectable HGF.
A number of different angiogenic factors, including VEGF andHGF,
have been implicated in the pathogenesis of CML [23–25]. The expres-
sion and release of most of these growth regulators in CML cells may be
triggered by the disease-specific oncoprotein, BCR-ABL1 [19,21,22].
Therefore, we were interested to learn whether BCR-ABL1 would also
promote the expression of HGF in leukemic cells. However, unexpect-
edly, BCR-ABL1 failed to induce expression of HGF in Ba/F3 cells
and MO7e cells. Moreover, imatinib failed to inhibit the production
of HGF in CML cells. By contrast, we were able to show that BCR-
ABL1 promotes expression of VEGF and HDC in Ba/F3 cells and that
imatinib inhibits expression of VEGF and HDC in CML cells, con-
firming previous studies [21]. These data suggest that, in contrast to
other angiogenic factors, HGF is expressed in CML cells independent
of BCR-ABL1. This is of particular interest because it has been postu-
lated that, in accelerated CML, BCR-ABL1–independent factors play a
particular pathogenetic role [6,8–10].
We next asked what factors, apart from BCR-ABL1, could play a
role in the production of HGF in leukemic cells. Because IL-3 is
known to induce differentiation and activation of human basophils
[30,31], we asked whether IL-3 would promote the expression of
HGF in leukemic cells. Our data show that IL-3 promotes the ex-
pression of HGF in primary CML cells as well as in highly enriched
(sorted) CML basophils. This observation suggests that apart from
BCR-ABL1, cytokine effects may play a role in the generation of
angiogenic factors in CML.
Although several studies have pointed at a potential prognostic value
of HGF in CML [23–25], only little is known about the functional
role of this angiogenic molecule in CML. So far, HGF levels have been
shown to correlate with BM angiogenesis in patients with CML. In
the present study, we asked whether basophil-derived HGF would
induce endothelial cell migration and growth. Indeed, recombinant
HGF as well as basophil-derived HGF were found to induce migration
and growth of endothelial cells in a scratch wound assay. The effects
of HGF in this assay were blocked by an anti-HGF antibody but
not by an anti-VEGF antibody, suggesting that the effects of HGF
on endothelial cells were specific and probably mediated through a
specific receptor.
HGF exerts effects on its targets cells through a specific receptor,
c-Met. We therefore asked whether endothelial cells express c-Met.
Indeed, cultured HUVECs were found to express c-Met mRNA as
well as surface c-Met protein. We also applied a pharmacologic
c-Met inhibitor to show that the effects of CML-derived and recom-
binant HGF are specific. In these experiments, the c-Met inhibitor
PF-2341066 was found to block endothelial cell migration induced
by recombinant HGF or CML-derived HGF. Together, these data
show that CML-derived HGF is a functionally active molecule that
may contribute to CML-associated angiogenesis.
A number of previous studies have shown that HGF regulates
growth and function of hematopoietic progenitor cells [35–39]. In
the present study, we asked whether CML cells express c-Met and
are responsive to HGF. As assessed by qPCR, CML basophils as well
as CD34+ CML cells were found to express c-Met mRNA. In addi-
tion, KU812 cells and K562 cells were found to express c-Met mRNA.
However, whereas KU812 cells expressed substantial amounts of c-Met
on their surface, K562 cells expressed only low amounts of c-Met in
our flow cytometry experiments, and primary CML cells were found
to express very low levels or even stained negative for c-Met. In func-
tional analyses, HGF induced a slight increase in proliferation of
KU812 cells and primary CML cells above control. In addition, a block-
ing anti-HGF antibody was found to suppress spontaneous growth of
KU812 cells, suggesting that HGF acts as an autocrine factor in these
cells. Moreover, the c-Met inhibitors PF-2341066 and SU11274 were
found to suppress the growth of primary CML cells as well as the
growth of KU812 cells and K562 cells. These results suggest that
the low amounts of c-Met in CML cells may be sufficient for mediat-
ing biologic activity. Alternatively, the c-Met inhibitor exerted “off
target effects” on CML cells and thereby introduced growth inhibition.
An interesting aspect is that relatively high drug concentrations were
required to produce growth inhibition in CML cell lines. However,
in primary CML cells, drug effects were within a pharmacologically
meaningful range, that is, around or below 1 μM.
In summary, our data show that basophils are a major source of
HGF in CML and that basophil-derived HGF acts as a potent para-
crine factor promoting endothelial cell migration and growth. Basophils
may play a more active role in disease acceleration in CML than has so
far been assumed. Whether basophils, basophil-derived HGF, or c-Met
could serve as therapeutic targets in CML remains to be elucidated.
Figure 7. Effects of c-Met inhibitors on growth of CML cells. (A) KU812 cells (left panels) and K562 cells (right panels) were incubated in
control medium (CO) or in medium containing various concentrations of the c-Met inhibitors PF-2341066 (upper panels) or SU11274
(lower panels) at 37°C and 5% CO2 for 48 hours. After incubation, uptake of
3H-thymidine was measured. Results are expressed as the
percentage of control (CO) and represent the mean ± SD of three independent experiments. (B) Ficoll-isolated mononuclear BM cells
(left panels) and PB cells (right panels) were incubated in control medium (CO) or in medium containing various concentrations of the
c-Met inhibitors PF-2341066 (upper panels) or SU11274 (lower panels) at 37°C and 5% CO2 for 48 hours. After incubation,
3H-thymidine
uptake was measured. Results are expressed as percentage of control and represent the mean ± SD of three independent experiments
(three patients). (C and D) KU812 cells were incubated in the absence (CO) or presence of various concentrations of the c-Met inhibitor
PF-2341066 at 37°C for 24 and 48 hours. After incubation, apoptosis was measured by light microscopy, Annexin V/PI staining, and
active caspase 3 staining by flow cytometry. In C, one typical experiment is shown for Annexin V/PI staining (left panel) and active caspase
3 staining (right panel) after 24 hours. In D, results show the percentage of Annexin V/PI–positive cells (upper panels: left panels, 24 hours;
right panels, 48 hours), the percentage of active caspase 3–positive cells (middle panels: left panels, 24 hours; right panels, 48 hours), and
the numbers of apoptotic cells by light microscopy (lower panels: left panels, 24 hours; right panels, 48 hours). Results represent the
mean ± SD of three independent experiments. *P < .05 compared with control (CO). (E) KU812 cells were incubated in control medium
(CO) or with the c-Met inhibitors PF-2341066 or SU11274 (each 1 μM) at 37°C for 4 hours. Then, cells were spun on cytospin slides and
stained with an antibody against phospho c-Met (magnification, 100×/1.35).
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Table W1. Characterization of Antibodies.
Antigen CD Clone* Name Fluorochrome Animal Source Isotype Provider Source
HPCA1 CD34 581 PE Mouse IgG1 BD Biosciences
ADP-RC CD38 HIT2 APC Mouse IgG1 BD Biosciences
LCA CD45 2D1 PerCP Mouse IgG1 BD Biosciences
ENNP CD203c 97A6G PE Mouse IgG1 Immunotech
c-Met n.c. 95106 PE Mouse IgG1 R&D Systems
Active caspase 3 n.c. C92605 PE Rabbit IgG1 BD Biosciences
rh Annexin — — FITC — — BD Biosciences
Isotype-Co — MOPC-21 PE Mouse IgG1 BD Biosciences
HGF n.c. H-145 (polyclonal) — Rabbit IgG Santa Cruz Biotechnology
Phospho-Met n.c. D26 — Rabbit IgG Cell Signaling
Basogranulin n.c. BB1 — Mouse IgG University of Southampton
ADP-RC indicates adenosine diphosphate ribosyl cyclase; APC, allophycocyanin; BD, Becton Dickinson; c-Met, c-mesenchymal epithelial transition factor; ENNP, ectonucleotide pyrophosphatase/
phosphodiesterase 3; FITC, fluoresceine isothiocyanate; HPCA1, human precursor cell antigen 1; IgG, immunoglobulin G; LCA, leukocyte common antigen; PE, phycoerythrin; PerCP, peridinin
chlorophyll protein.
*All antibodies except H-145 were monoclonal antibodies (mAb).
Table W2. Primer Sequences Used to Generate Northern Blot Probes.
Gene Sequence
mu HGF-fwd 5′-GCCAGAAAG ATATCCCGACA-3′
mu HGF-rev 5′-AACTCGGATGTTTGGGTCAG-3′
mu-hu Actin-fwd 5′-GACGGCCAG GTCATCACTAT-3′
mu-hu Actin-rev 5′-AGGGAGACCAAAGCCTTCAT-3′
hu c-Met-fwd 5′-CAGGCAGTGCAGCATGTAGTG-3′
hu c-Met-rev 5′-TAAGGTGGGGCTCCT CTTGTCA-3′
fwd indicates forward; hu, human; mu, murine; rev, reverse.
Table W3. Oligonucleotide Primer Sequences for qPCR.
Gene Sequence
mu HDC-fwd 5′-ACT CCA GTG CAG CCT GGA TAC C-3′
mu HDC-rev 5′-GGC TAG ATG CCC ACG TGA ATC CTA A-3′
mu HGF-fwd 5′-GGC ATC AAA TGC CAG CCT TG-3′
mu HGF-rev 5′-CGC GAT AGC TCG AAG GCA AA-3′
mu-hu Actin-fwd 5′-TCG ACA ACG GCT CCG GCA TG-3′
mu-hu Actin rev 5′-CCT CTC TTG CTC TGG GCC TCG TC-3′
hu c-met-fwd 5′-CGGACCCAATCATGAGCACTG-3′
hu c-met-rev 5′-ATCACGGCGCGCTTCACAG-3′
hu HDC-fwd 5′-GGA GAC ATG CTG GCT GAT GC-3′
hu HDC-rev 5′-TCT GTA CAC GCA GGG CTG GA-3′
hu HGF-fwd 5′-CAT CGC CAT CCC CTA TGC AG-3′
hu HGF-rev 5′-TGA TTA GGG TAG TCT TTG CTG ATT TT-3′
huVEGF-fwd 5′-GTC GGG CCT CCG AAA CCA TG-3′
hu VEGF-rev 5′-CTG GAT GAT TCT GCC CTC CTC CTT C-3′
hu Abl-fwd 5′-TGT ATG ATT TTG TGG CCA GTG GAG-3′
hu Abl-rev 5′-GCC TAA GAC CCG GAG CTT TTC A-3′
Figure W1. Scores for evaluating endothelial migration in the
scratch wound migration assay: 0, scratch area empty (no cells
migrated); I, few single endothelial cells in scratch wound; II, multi-
ple isolated endothelial cells in scratch lesion; III, endothelial cells
form aggregates and bridges in scratch wound; IV, scratch wound
completely “healed” (confluent layer).
Figure W2. Reactivity of CML basophils with an anti-HGF antibody
and effects of a HGF-specific blocking peptide. ICC detection of HGF
in KU812 cells (A, upper panels) and isolated BM cells (B, middle
panels) obtained from a patient with CML in AP. Before staining, the
anti-HGF antibody was preincubated in control buffer (left panels) or
with a HGF-specific blocking peptide (right panels). (C) Adjacent BM
sections obtained from a patient with CML AP were stained with an
anti-HGF antibody. Before staining, the anti-HGF antibody was pre-
incubated in control buffer (left panel) or with a HGF-specific blocking
peptide (right panel). Images were produced using an Olympus DP21
camera connected to an Olympus BX50F4microscope equipped with
40×/0.85 UPlan-Apo objective lens (Olympus). Figures were prepared
using Adobe Photoshop CS2 software version 9.0 (Adobe Systems,
San Jose, CA) and PowerPoint software (Microsoft, Redmond, WA).
Figure W3. IL-3 regulates the expression and release of HGF in CML
cells. (A) Expression of HGF mRNA in PB MNCs and highly purified
(sorted CD203c+) basophils (BA+) from three patients with CML.
Basophils were incubated in the presence and absence of IL-3
(100 ng/ml) for 30 minutes and then subjected to RNA isolation,
cDNA synthesis, and qPCR using primers specific for HGF and
ABL. Results show HGF mRNA expression levels as percent of ABL
mRNA levels and represent themean± SD of three donors. *P< .05.
(B) Expression of HGF mRNA in PB MNC of three patients with CML
withmarked basophilia (>10%). Cells were incubated in the presence
or absence of IL-3 (100 ng/ml) for 8 hours. Then, RNA was isolated,
and qPCR was performed using primers specific for HGF and ABL.
Results showHGFmRNA expression levels as percent of ABLmRNA
levels and represent the mean ± SD of three donors. *P < .05. (C)
Measurement of HGF in supernatants of PB MNC of patients with
CML with basophilia (>10%). Cells were incubated in the presence
or absence of IL-3 (100 ng/ml). Supernatants were collected after
5 days, and HGF concentrations were determined by ELISA. Results
represent the mean ± SD of three independent experiments.
Figure W4. Effects of the c-Met inhibitor PF-2341066, rhHGF and
an anti-HGF antibody on endothelial cell (HUVECs) migration in a
scratch wound assay. (A) After producing a scratch wound into
confluent layers of HUVECs by a pipette tip, cells were incubatedwith
rhHGF (100 ng/ml) in the absence (CO) or presence of various con-
centrations of the c-Met inhibitor PF-2341066 at 37°C for 24 hours.
Endothelial cell migration was examined under an inverted micro-
scope (Eclipse TE 300; Nikon). Cell density in the scratch wound
was scored from 0 to 4 (see also Figure W1): 0, scratch area empty
(no cells migrated); I, few single endothelial cells in scratch wound;
II, multiple isolated endothelial cells in scratch lesion; III, endothelial
cells form aggregates and bridges in scratch wound; IV, scratch
wound completely “healed” (confluent layer). Results represent
the mean ± SD of three independent experiments. (B) After pro-
ducing a scratch wound into confluent layers of HUVECs by a
pipette tip, cells were incubated in the absence or presence of
rhHGF (100 ng/ml) and a neutralizing anti-HGF antibody (αHGF;
60 ng/ml) at 37°C for 24 hours. Endothelial cell migration was
examined under an inverted microscope (Eclipse TE 300; Nikon).
Cell density in the scratch wound was scored from 0 to 4 (see
also Figure W1). Results represent the mean ± SD of three inde-
pendent experiments.
Figure W5. Surface expression of c-Met on CML basophils and
CML CD34+/CD38− cells after incubation with IL-3. (A) Surface
expression of c-Met on CML basophils after incubation in the pres-
ence and absence (CO; black histograms) of IL-3 (100 ng/ml; red
histograms) for 8 hours at 37°C. Cells were analyzed for expression
of c-Met by multicolor flow cytometry. Expression of c-Met was
controlled by an isotype-matched antibody (gray open histograms).
(B) Surface expression of c-Met on CML CD34+/CD38− cells after
incubation in the presence and absence (CO) (black histograms) of
IL-3 (100 ng/ml, red histograms) for 8 hours at 37°C. Cells were
analyzed for expression of c-Met by multicolor flow cytometry.
The expression of c-Met was controlled by an isotype-matched
antibody (gray open histograms).
Figure W6. Effects of rhHGF on primary CML cells. Ficoll isolated
mononuclear (MNC) BM cells (A) and PB cells (B) were incubated
in control medium (CO) or in medium containing various concentra-
tions of rhHGF at 37°C and 5% CO2 for 48 hours. After incubation,
0.5 μCi of 3H-thymidine was added. Twelve hours later, cells were
harvested, and bound radioactivity was measured in a β-counter.
Results are expressed as the percentage of control (CO) and repre-
sent the mean ± SD of three independent experiments. *P < .05.
